Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Donor stem cells injected into knees: safe or not?

NCT ID NCT06084988

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested whether a single injection of donor bone-marrow stem cells (StromaForte) is safe for people with mild-to-moderate knee osteoarthritis. Twelve adults received the injection and were monitored for side effects over 24 weeks. The main goal was safety, not pain relief or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

12 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide written informed consent and comply with all procedures required by the protocol 2. Aged \> 18 years at the time of signing the informed consent form 3. Diagnosed with knee OA according to American College and Rheumatology criteria and showing a stage of a mild to moderate arthritis. 4. Kellgren-Lawrence radiological classification scale II and III at screening 5. Visual analogue scale (VAS) joint pain ≥ 2.5 at screening 6. Have tried but failed conservative management including physical therapy, bracing and medications for a minimum of three months. 7. No history of prior intra-articular cortisone, hyaluronic acid, or platelet-rich plasma injection within the previous six months 8. No history of prior arthroscopic knee surgery or open knee surgery on the ipsilateral side within the past year 9. Adequate liver and renal functions with non-malignant blood profile. 10. Body Mass Index between 20 and 30 kg/m2 11. Negative for (HIV, HTLV1\&2, Hep A, B, C, syphilis) infection as determined by approved serological testing 12. Negative for pregnancy as determined by a serum pregnancy test. Females of childbearing potential will be required to practice abstinence or use an effective form of contraception for 12 months following their MSC injection. 13. Fluid \> 1 cm within the lateral recess of the suprapatellar pouch at the level of the superior pole of the patella with the knee extended. Exclusion Criteria: 1. Unwilling or unable to perform any of the assessments required by the protocol 2. Patients with clinically unstable knee due to the presence of a complete anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament and/or posterolateral corner tear 3. Patients with varus or valgus malalignment \>5 degrees as measured by 4-foot standing antero-posterior radiographs 4. Patients with a history of a previous subtotal medial or lateral meniscectomy 5. Patients with a history of septic arthritis in the affected joint 6. Patients with a history of a prior intra-articular knee fracture 7. Severe bleeding diathesis 8. Active infection 9. Patients with unforeseen conditions that are deemed unsafe or inappropriate for the study (e.g., patients who are claustrophobic and cannot undergo an MRI) as per the discretion of the principal investigator 10. Patients with neoplasia 11. Patients participating in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in this study 12. Patients with a known history of inflammatory or rheumatic diseases such as rheumatoid arthritis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Burjeel Medical City

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.